GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BiVictriX Therapeutics PLC (LSE:BVX) » Definitions » Cash Flow from Others

BiVictriX Therapeutics (LSE:BVX) Cash Flow from Others : £0.50 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is BiVictriX Therapeutics Cash Flow from Others?

BiVictriX Therapeutics's cash flow from others for the six months ended in Jun. 2024 was £-0.01 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Jun. 2024 was £0.50 Mil.


BiVictriX Therapeutics Cash Flow from Others Historical Data

The historical data trend for BiVictriX Therapeutics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BiVictriX Therapeutics Cash Flow from Others Chart

BiVictriX Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Others
Get a 7-Day Free Trial 0.11 0.14 0.73 0.21 0.52

BiVictriX Therapeutics Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 0.21 - 0.51 -0.01

BiVictriX Therapeutics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.50 Mil.

BiVictriX Therapeutics Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of BiVictriX Therapeutics's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


BiVictriX Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Alderley Edge, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG
BiVictriX Therapeutics PLC is a drug development company. It has developed its proprietary Bi-Cygni technology which utilizes Antibody Drug Conjugates for the treatment of various cancers including Acute Myeloid Leukaemia. The Group has one reportable segment, being the development of pharmaceutical products within the United Kingdom.

BiVictriX Therapeutics Headlines

No Headlines